Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trialJonas Bergh, Nils Wilking, S. Ottosson et al.|The Lancet|2000Cited by 343
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Nils‐Olof Bengtsson, Lena Carlsson et al.|Acta Oncologica|2010Cited by 19
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, I. Thalmann, Volker Möbus et al.|Journal of Clinical Oncology|2024Cited by 11
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Jonas Bergh, Sara Margolin et al.|Breast Cancer Research and Treatment|2017Cited by 8
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapyAnna Nordenskjöld, Bo Nordenskjöld, Helena Fohlin et al.|The Breast|2023Cited by 7